Regulatory evaluation of Glybera in Europe-two committees, one mission by Melchiorri, Daniela et al.
L I N K  TO  O R I G I N A L  A RT I C L E
Representing the first gene therapy to be 
approved in the Western world, alipogene 
tiparvovec (Glybera; Uniqure) has recently 
been said to have had a “substantial impact 
from a regulatory perspective” (Nature Rev. 
Drug Discov. 11, 664; 2012)1. The therapy 
was granted marketing authorization in 
the European Union for the treatment of 
lipoprotein lipase deficiency, which results 
in a clinically heterogeneous condition with 
a risk of potentially life-threatening pan-
creatitis2, at the end of 2012. The decision 
followed a positive opinion by the European 
Medicines Agency (EMA)’s Committee 
for Medicinal Products for Human Use 
(CHMP)3, and a previous recommenda-
tion of the EMA’s Committee for Advanced 
Therapies (CAT)4,5.
The approval process for Glybera was 
extensively discussed in the scientific  
community, sometimes critically6–12. During 
the process, the opinions of the CHMP and 
the CAT differed: although the opinion of 
both committees was originally negative,  
in a “re-examination procedure” the opinion 
of the CAT became positive5, whereas the 
CHMP maintained its negative opinion13. 
However, both committees finally recom-
mended approval of the medicine. As regula-
tors who have been involved in this approval 
process, we would like to provide insight 
into why the Glybera procedure was chal-
lenging, and give assurance to the scientific 
community regarding confidence in both 
orphan drug and gene therapy regulation 
in Europe.
The approval process for Glybera
In Europe, gene therapies undergo a  
centralized approval procedure via the EMA. 
For advanced therapy medicinal products 
(ATMPs), which include gene therapies, the 
CAT as an expert committee first performs 
a scientific assessment of the application 
dossier and prepares a draft opinion on 
its approvability for a final decision by the 
CHMP, a committee with considerable 
long-term expertise, which also ensures  
consistency in the opinions.
The assessment process for Glybera 
was long and complex owing to multiple 
reasons. These included the complexity of 
the product class for which there was little 
previous regulatory experience (this was the 
first procedure for a gene therapy to cor-
rect a genetic deficiency); the long product 
development time, during which science 
evolved and specific regulatory requirements 
were about to be established; the complex 
disease scenario (a very rare disease) with a 
fluctuating clinical outcome (pancreatitis); 
and the fact that the company was small with 
academic origins (as usually also seen for 
other ATMPs)14.
The applicant’s total clinical programme 
included 27 patients with lipoprotein lipase 
deficiency on a low-fat diet2. At first, the 
main measure of efficacy was based on 
a reduction in blood triglyceride levels. 
However, this was later changed to post-
prandial chylomicrons, as this biomarker 
was thought to more specifically address 
the pharmacodynamic effect of Glybera, 
whereas the effect on triglyceride levels 
was only short-lived. This raised additional 
issues during the scientific review: were 
the data robust enough for a previously 
non-validated biomarker (postprandial 
chylo microns) in the presence of more 
inconclusive clinical evidence (pancrea-
titis)? Should data from that biomarker be 
accepted as pivotal evidence for activity,  
as it was scientifically better fitted to measure 
the treatment effect (as recommended by 
an ad hoc scientific advisory group to the 
CAT and CHMP) than the one originally 
defined in the protocol (triglyceride levels)? 
Or should one rather focus on that (for-
mally failed) primary end point? There were 
only a handful of patients from the study 
population for whom such data on the  
newly proposed biomarker were available, 
and even fewer for a sustained period.
Although different opinions were issued 
by the two committees during the procedure, 
both committees were consistent in their 
scientific judgement when the details were 
considered. The CHMP acknowledged the 
promising nature of the data by an almost 
unprecedented “positive tone” when draft-
ing its initial negative opinion, so as to 
demonstrate that it would be prepared to 
reconsider the case once more specific and 
supportive data had been collected (and here 
the vast majority of the CHMP agreed). The 
CHMP was clearly of the view that develop-
ment should continue. We consider that 
both committees had already, at that time, 
taken major steps towards finding a way for 
ATMPs to be used for the treatment of very 
rare diseases, by considering all data rather 
than single outcome measures. Both com-
mittees considered that evolution of scientific 
knowledge can make the appreciation of 
an emerging, biologically more plausible 
biomarker necessary, if well justified and 
supported by data. Both committees were 
well aware that the acceptance of a limited 
data set was a double-edged sword, as it 
could be perceived as lowering the standards. 
However, this was not the case: both  
committees agreed that the limited clinical 
efficacy and safety data set needed to be  
supplemented by additional data.
The opinion of the two committees dif-
fered on the stage at which such additional 
data should be submitted: before approval 
(as initially preferred by the CHMP) or after 
approval (as recommended by the CAT).  
It is important to note that the final positive 
outcome was, to a major extent, also driven 
by an appreciation of the specific clinical 
scenario of lipoprotein lipase deficiency. 
Assessing orphan drugs in ‘ultra-rare’  
conditions (here defined as a prevalence of 
less than 1 in 100,000) was not new to the 
CHMP; several drugs are already licensed for 
conditions with such low prevalence (FIG. 1).  
However, all of these conditions follow 
either a continuously progressive course of 
deterioration or a very active disease course if 
left untreated (TABLE 1). The effect of a thera-
peutic intervention for such conditions is 
therefore easier to measure within a relatively 
short timeframe.
Furthermore, surrogate markers for  
clinical outcome existed for these conditions 
(TABLE 1). By contrast, lipoprotein lipase  
deficiency results in pancreatitis in  
otherwise often phenotypically healthy  
individuals — a complication that is not  
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Figure 1 | Authorized orphan drugs and ultra-orphan conditions. 
Orphan conditions with authorized treatments (at least one per condition) 
are ordered by prevalence (number of patients per 10,000 in the European 
Union). Analysis from data on file at the European Medicines Agency 
(EMA; cut-off: November 2012); in situations where a condition was listed 
more than once (and with varying prevalence), the lowest prevalence was 
listed. Ultra-rare conditions (the boxed indications in the figure) were 
defined as having a prevalence of equal to or less than 0.1 per 10,000 persons 
in the European Union. Lipoprotein lipase deficiency, targeted by Glybera 
(alipogene tiparvovec), represents the third rarest disease for which a 
medical treatment has so far been authorized. The pivotal data submitted 
for these ultra-rare conditions are listed for comparison in TABLE 1. ALL, 
acute lymphoblastic leukaemia; CEL, chronic eosinophilic leukaemia; 
CFTR, cystic fibrosis transmembrane conductance regulator; HPC, haema-
topoietic progenitor cell; Ph+, Phila delphia chromosome positive; SGCA, 
subependymal giant cell astrocytoma. *Treatment in patients who require 
intrathecal analgesia. ‡With platelet-derived growth factor receptor 
(PDGR) gene rearrangements. §C1 esterase inhibitor deficiency.
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only influenced by various factors including  
diet, but that also exhibits a much more 
unpredictable and fluctuating disease course 
with intermittent healthy periods. Therefore, 
it would — in theory — be necessary to 
conduct either a large clinical study enabling 
for a sufficiently high event rate (which is 
not feasible for an ultra-rare disease) or a 
long follow-up in order to detect a sufficient 
number of events in a smaller patient  
population (how long would be feasible in 
a pre-approval situation?). So, to counter-
balance the inherent limitations of the  
clinical database, an approval “under excep-
tional circumstances”15 with post-approval 
supplementation of the database was the 
most appropriate route.
The way forward
In our view, the message to the scientific 
community is positive: both committees had 
complementary approaches. They delivered 
within the spirit of the legislation and took a 
scientific approach recognizing the rarity of 
the disease and the difficulties in obtaining 
comprehensive data. They acknowledged 
the evolution of science and considered the 
data as a whole. It is common in science 
that in borderline situations two experts can 
reach different conclusions when balancing  
certainties and uncertainties. However, 
this balanced and weighted scientific view 
of both committees, as briefly highlighted 
here, resulted in a seemingly ‘black and 
white’ outcome, as for a regulatory opinion 
there are only two possible decisions  
(positive or negative), and only this was  
visible to the scientific community.
During the approval procedure the two 
committees closely collaborated, and they 
will continue to strengthen their collabora-
tion based on increasing experience. This 
will be facilitated by the recent inauguration 
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End points included not only clinical end points but also biochemical readouts or other biomarkers. Source: European Public Assessment Reports.























which involves all chairpersons of the EMA 
committees. We do not agree that this is “the 
perfect bureaucratic response”17, as it is not 
another committee that complicates proce-
dures but a body that takes a more strategic 
and coordinative role under the umbrella of 
the EMA’s missions and visions. Its creation 
is not a consequence of the Glybera pro-
cedure, but a logical step towards the fulfil-
ment of the EMA’s goal to ensure efficient 
operation of its core business — principles 
that were already published in early 2011 
(REF. 18).
The role of the CAT was recently chal-
lenged6–12, given that the CHMP is required 
by legislation to make the final opinion. 
This may be perceived as though the CAT 
is not heard, or that it lacks the power to 
foster innovation and create a fruitful envi-
ronment for its stakeholders to develop 
and gain the approval of ATMPs. However, 
this assumption is not only incorrect but 
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also oversimplified. Besides the fact that 
the CHMP fully supports innovation, the 
CAT has considerable influence at the early 
stage of ATMP development, for example, 
by systematically reviewing and discussing 
the CHMP’s scientific advice procedures 
for ATMPs, by participating in the innova-
tion task force meetings concerning ATMPs 
at the EMA, or when issuing certificates 
on quality and/or non-clinical data. The 
approach that the legislator had taken when 
drafting the ATMP regulation was not 
intended to separate the licensing pro cedure 
for ATMPs from that of other human 
medicines; it would be difficult to explain 
to patients why an ATMP should have a dif-
ferent standard compared to a conventional 
medicine, and it would not be helpful to 
exclude the CHMP’s extensive experience of 
reviewing dossiers including those for drugs 
targeting rare diseases.
In conclusion, we submit that both 
committees’ deliberations and conclusions 
illustrate their openness towards innovative 
approaches to drug development and their 
willingness to exercise flexibility where  
scientifically appropriate. The history  
summarized above also provides a reminder 
of the regulators’ challenge to balance early 
availability of promising treatments with  
a need to uphold appropriate standards  
of evidence, and in borderline situations a  
different opinion of independent experts  
can never be fully excluded. We contend  
that a ‘black and white’ view of the  
regulatory procedure for Glybera (or 
any other similar scenario), as has been 
expressed in the literature, is not correct; 
rather, the opinions of the two committees 
illustrate the shades of grey involved in  
such procedures and also highlight the 
shared dedication of the committees to 
patients and innovation.
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